Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: Pre-clinical rationale and preliminary results of clinical trials

Progress in Experimental Tumor Research

Volumn 37, Issue , 2003, Pages 243-260

  Blanke, Charles D ^a   Masferrer, Jaime L ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; MICROTUBULE; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MICROTUBULES; NEOPLASMS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0043133520     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071376     Document Type: Article

References (62)

1. Turini ME, DuBois RN: Cyclooxygenase-2: A therapeutic target. Annu Rev Med 2002;53:35-57.
2. Lipsky PE, Brooks P, Crofford LJ, DuBois R, Graham D, Simon LS, van de Putte LB, Abramson SB: Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000;160:913-920.
3. Eberhart CE, Coffey RJ, Radhika A, Giardello FM, Ferrenbach S, DuBois RN: Upregulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188.
4. Blanke CD: Role of COX-2 inhibitors in cancer therapy. Cancer Invest 2002 (in press).
5. Kazuhiko U, Ichikura T, Mochizuki H: Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001;76:26-30.
6. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SEA: Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96: 990-996.
7. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki KI, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T: Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764.
8. Ohno R, Yoshingaga K, Fujita T, Hasegawa K, Iseki H, Tsunozaki H, Ichikawa W, Nihei Z, Sugihara K: Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001;91:1876-1881.
9. Ratnasinghe D, Tangrea J, Roth MJ, Dawsey S, Hu N, Anver M, Wang QH, Taylor PR: Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; An immunohisto-chemical survey. Anticancer Res 1999;19:171-174.
10. Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano Y, Yashima K, Kishimoto Y, Kawasaki H: Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999;46:407-412.
11. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
12. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB, Kim HC: Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6:519-525.
13. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki KI, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahasi T: Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-1005.
14. Tomozawa S, Tsuno NH, Sunami E: Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83: 324-328.
15. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJA, Van Lanshot JJB, Ristimaki A: Prognostic significance of elevated cyclooxygenase-2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800-1807.
16. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
17. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-3340.
18. Moos PJ, Fitzpatrick FA: Taxane-mediated gene induction is independent of microtubule stabilization: Induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 1998;95:3896-3901.
19. Gemsa D, Kramer W, Brenner M, Till G, Resch K: Induction of prostaglandin E release from macrophages by colchicine. J Immunol 1980;124:376-380.
20. 2 production in osteoblastic cells. Biochim Biophys Acta 1987;927:315-323.
21. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ: Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 2000;275:14838-14845.
22. Subbaramaiah K, Marmo TP, Dannenberg A: Taxotere induces cyclooxygenase-2 by enhancing transcription and mRNA stability. Proc Am Assoc Cancer Res 2002, abstr 343.
23. Chodkiewicz C, Gomez JE, Ling YH, Perez-Soler R: Cyclooxygenase-2 expression and in vitro and in vivo sensitivity to paclitaxel in non-small cell lung cancer. Proc Am Assoc Cancer Res 2000, abstr 508.
24. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-2011.
25. Teicher BA, Korbut TT, Menon K, Holden SA, Ara G: Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol 1994;33:515-522.
26. Moore RJ, Zweifel BS, Heuvelman DM, Leahy KM, Edwards DA, Woerner BM, Ornberg RL, Seibert K, Koki AT, Masferrer JL: Enhanced antitumor activity by co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-FU. Proc Am Assoc Cancer Res 2000, abstr 2600.
27. Trifan OC, Masferrer JL: Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002;62:5778-5784.
28. 2 and water absorption of large intestine in rats. Jpn J Pharmacol 1997;75:399-405.
29. Lorenz M, Slaughter HS, Wescott DM, Carter SI, Schnyder B, Dinchuk JE, Car BD: Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp Hematol 2000;28:741-742.
30. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas L: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326-1331.
31. Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ, Dodson M: Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001;49:1213-1217.
32. Formenti SC, Spicer D, Skinner K, Cohen D, Corso F, Bettini A, Muggia F, Danenberg K, Danenberg P: Pre-operative twice weekly paclitaxel and radiation therapy in locally advanced breast cancer: Molecular determinants of pathological response. Proc Am Soc Clin Oncol 1999, abstr 282.
33. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-954.
34. Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G, the FAP Study Group: A randomised, double-blind, placebo-controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-860.
35. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
36. Csiki I, Dang T, Gonzalez A, Sandler A, Carbone D, Choy H, Campbell N, Garcia B, Morrow J, Johnson DH: Cyclooxygenase-2 inhibition + docetaxel in recurrent non-small cell lung cancer: Preliminary results of a phase II trial (THO-0054). Proc Am Soc Clin Oncol 2002;21:297a (abstr 1187).
37. Carbone D, Choy H, Csiki I, Dang T, Campbell N, Garcia B, Morrow J, Saha D, Johnson DH, Sandler A: Serum/plasma VEGF level changes with cyclooxygenase-2 inhibition in combined modality therapy in stage III non-small cell lung cancer: Preliminary results of a phase II trial (THO-0059). Proc Am Soc Clin Oncol 2002;21:318a (abstr 1270).
38. Altorki NK, Keresztes RS, Port JL, Flieder DB, Ferrara CA, Pasmantier MW, Libby DM, Yankelevitz D, Dannenberg AJ: Celecoxib, a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer. Proc Am Soc Clin Oncol 2002;21:26a (abstr 101).
39. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ: Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-4429.
40. Dang CT, Dickler MN, Moasser MM, Theodoulou M, Seidman A, Norton L, Hudis CA: Celecoxib and trastuzumab is feasible after herceptin for HER-2/neu overexpressing metastatic breast cancer patients. Proc Am Soc Clin Oncol 2002;21:48b (abstr 2003).
41. 716 knockout mice by inhibition of cyclooxygenase-2. Cell 1996;87:803-809.
42. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM: Size- and invasion-dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res 1998;58: 4823-4826.
43. Sinicrope FA, Pazdur R, Levin B: Phase I trial of sulindac plus 5-fluorouracil and levamisole: Potential adjuvant therapy for colon carcinoma. Clin Cancer Res 1996;2:37-41.
44. Blanke CD, Benson AB III, Dragovich T, Lenz HJ, Haller D, Robles C, Buchbinder A: A phase II trial of celecoxib, irinotecan, 5-fluorouracil, and leucovorin in patients with unresectable or metastatic colorectal cancer. Proc Am Soc Clin Oncol 2002;21:127a (abstr 505).
45. Sweeney C, Seitz D, Ansari R, Chowhan N, Pletcher W, Vinson J, Stoner C, Sawi J, Loehrer PJ: A phase II trial of irinotecan, 5-fluorouracil, leucovorin, celecoxib and glutamine as first-line therapy for advanced colorectal cancer: A Hoosier Oncology Group study. Proc Am Soc Clin Oncol 2002;21:105b (abstr 2235).
46. Lin EH, Morris J, Chau NK, Crane C, Wolff R, Janjan N, Xiong H, Delcos M, Abbruzzese JL: Celecoxib attenuated capecitabine induced hand-and-foot syndrome and diarrhea and improved time to tumor progression in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2002;21:138b (abstr 2364).
47. Becerra CR, Frenkel EP, Gaynor R: A phase II study of 5-fluorouracil and leucovorin calcium plus open-label rofecoxib in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2002; 21:107b (abstr 2240).
48. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ 3rd: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-990.
49. Ding XZ, Tong WG, Adrian TE: Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000;20:2625-2631.
50. Xiong HQ, Du M, Wolff RA, Lenzi R, Dumas P, Lassere Y, Plunkett W, Abbruzzese JL: Pharmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Proc Am Soc Clin Oncol 2002;21:113a (abstr 448).
51. Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS: High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000;76:320-325.
52. http://www.RTOG.org
53. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, Seyfried NT, Abc T, Chen LB, Carroll RS, Black PM: Expression of cyclooxygenase-2 in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 2001;60:4926-4931.
54. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF: Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 2001;61:4375-4381.
55. http://www.mdanderson.org
56. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-78.
57. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-596.
58. Chaudry AA, Wahle KW, McClinton S, Moffat LE: Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: Effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994;57:176-180.
59. Liu XH, Yao S, Kirschenbaum A, Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58: 4245-4249.
60. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-825.
61. http://www.ohsu.edu/oci/trials.shtml
62. Kerbel RS, Klement G, Pritchard KI, Kamen B: Continuous low-dose anti-angiogenic metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol 2002; 13:12-15.